Advanced Search

Management of Primary Open-Angle Glaucoma and Ocular Hypertension: The Potential Role of Latanoprost

Contents:

Author Info

  • Julia A. Balfour

    (Adis International Limited, Auckland, New Zealand)

  • Julie C. Adkins

    (Adis International Limited, Auckland, New Zealand)

Registered author(s):

    Abstract

    Primary open-angle glaucoma (POAG) is a chronic progressive disease characterised by damage to the optic nervehead (optic disc) which leads to visual field loss and may eventually result in blindness if left untreated. Intraocular pressure (IOP) is elevated in the majority of patients. Early intervention, based on reduction of IOP, can prevent or delay visual impairment and topical ocular hypotensive therapy is the mainstay of management. Argon laser trabeculoplasty or filtration surgery are most often used after failure of topical therapy but are also used as the initial intervention in some cases. Latanoprost is an ester prodrug analogue of prostaglandin F2a available for the topical management of open-angle glaucoma and ocular hypertension. It lowers diurnal IOP by approximately 25 to 35%, by enhancing uveoscleral outflow of aqueous humour. This mechanism differs from that of other ocular hypotensive agents. Because its ocular hypotensive effects last for at least 24 hours after a single dose, latanoprost is administered once daily. Comparative studies have shown that latanoprost 0.005% once daily is more effective than timolol 0.5% twice daily in lowering IOP. Additional reductions in IOP are achieved when latanoprost is used in combination with topical timolol or dipivefrin, or with oral acetazolamide. The most common local adverse effects associated with latanoprost are eye irritation (burning, stinging, tearing and/or itching), mild conjunctival hyperaemia, superficial punctate keratopathy and foreign body sensation. Increased pigmentation of the iris occurs in a variable proportion of patients treated with latanoprost. This phenomenon appears to be permanent, is most likely to occur in eyes with mixed iris colour and its long term clinical significance is unknown. In contrast with timolol, latanoprost is not associated with systemic adverse effects, having essentially no effect on heart rate or systemic blood pressure. Latanoprost is currently recommended for use in patients who respond inadequately to, or are unable to tolerate, other ocular hypotensive agents, or as first-line therapy, depending on the market. However, it has a number of favourable properties, which suggests that it has considerable potential for much wider use. Although further long term tolerability data are required, it appears possible that latanoprost and other topical prostaglandin analogues might largely replace beta-adrenergic antagonists as first-line therapy for management of POAG and ocular hypertension in the future.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://diseasemanagement.adisonline.com/pt/re/dmo/pdfhandler.00115677-199804020-00004.pdf
    Download Restriction: Pay per view
    File URL: http://diseasemanagement.adisonline.com/pt/re/dmo/fulltext.00115677-199804020-00004.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Wolters Kluwer Health | Adis in its journal Disease Management & Health Outcomes.

    Volume (Year): 4 (1998)
    Issue (Month): 2 ()
    Pages: 101-112
    Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
    Handle: RePEc:wkh:dmhout:v:4:y:1998:i:2:p:101-112

    Contact details of provider:
    Web page: http://diseasemanagement.adisonline.com/

    For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).

    Related research

    Keywords: Reviews-on-treatment; Glaucoma; Ocular-hypertension; Ophthalmic-preparations; Eye-surgery; Dorzolamide; Brinzolamide; Research-and-development; Carbonic-anhydrase-inhibitors; Latanoprost; Prostaglandins;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:dmhout:v:4:y:1998:i:2:p:101-112

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.